现实世界的研究结合局部干预与系统治疗在不可切除的肝细胞癌
Zhaosong Xue1, Ming Yao1, Kang Chen1
1Department of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, 530007, Guangxi, China.
Scientific reports
|February 5, 2025
概括
结合局部干预,氨酸激酶抑制剂 (TKIs) 和抗PD-1抗体的三重疗法对不可切除的肝细胞癌 (HCC) 有希望. 治疗后切除改善了生存率,关键因素影响了资格和结果.
科学领域:
- 肝胆道手术 肝胆道手术
- 医学瘤学 医学瘤学
- 免疫治疗是一种免疫疗法.
背景情况:
- 无法切除的肝细胞癌 (HCC) 存在重大治疗挑战.
- 三重治疗 (局部干预,TKI,抗PD-1) 显示有效性,但长期存活不清楚.
研究的目的:
- 评估三重疗法对不可切除的HCC的长期生存结果.
- 确定预测成功转换切除和术后复发的因素.
- 评估肝切除术对整体存活时间的影响.
主要方法:
- 79名最初无法切除的HCC患者接受三重治疗的回顾性分析 (2020年1月至2022年12月).
- 基于治疗反应的转化肝切除术的选择标准.
- 对与切除和存活相关的临床因素的统计分析.
主要成果:
- 20名患者 (25.3%) 在三重治疗后实现了R0切除.
- 没有额外肝脏疾病和放射性反应预测了切除的资格.
- 肝切除术与有利的整体存活率 (HR 0.388) 独立相关.
- 肝外转移,瘤数 ≥4 和缺乏放射性缓解是不良的预后因素.
- 12个月无复发和整体生存率为43.3%和66.6%的切除患者.
结论:
- 三重疗法为不可切除的HCC提供了有利的预后结果和可管理的安全性.
- 在三重疗法后的转化切除显著改善了整体存活率.
- 基于疾病程度和治疗反应的患者选择对于成功的手术转换至关重要.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.8K
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.1K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...